Innovative AI solutions from soventec in the fight against pancreatic cancer

As part of the MMAIC-IPMN research project, soventec GmbH is significantly involved in the early detection and risk assessment of pancreatic precancerous lesions (IPMN). The aim is to use artificial intelligence and state-of-the-art software technology to detect the risk of developing pancreatic cancer at an early stage and improve the monitoring of affected patients.

To this end, soventec is developing special software modules that merge and evaluate large volumes of patient data from various databases and create individual risk profiles using an AI model. On this basis, so-called artificial cohorts are created, which enable a patient-oriented and explainable risk assessment. This allows targeted monitoring and treatment strategies to be derived.

The experienced soventec team ensures that the new AI-based analysis methods are used both in research and, in the long term, in everyday clinical practice and as a lab-on-a-chip solution. In addition, the know-how will be used and further developed in future projects and services - for an innovative and personalized medicine of the future.

Project partners:

•   Universitätsklinikum Schleswig-Holstein
•  Universität zu Lübeck
•  Hahn-Schickard-Gesellschaft für angewandte Forschung e.V.